Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Taipei, etc., Taiwan Clinical Trials

A listing of Taipei, etc., Taiwan clinical trials actively recruiting patients volunteers.

RESULTS

Found (598) clinical trials

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.

Phase

0.0 miles

Learn More »

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. ...

Phase

0.69 miles

Learn More »

This study will enable patients receiving sorafenib (Nexavar) in the completed Bayer/Onyx sponsored clinical trials to continue treatment. During the entire course of the study, numerous patients will be treated with sorafenib. Involvement in this study will be depending on whether the patient benefits from the treatment or not, based ...

Phase

0.69 miles

Learn More »

The Establishment of the Early Intervention Program for Patients With Schizophrenia

Schizophrenia is a severe mental illness, which has a prodromal phase of 1-2 years prior to the onset of the illness. During the prodromal phase, patients might show maladaptation and/or poor social functioning. However, these early symptom of schizophrenia might be overlooked by patients and their families. At that period, ...

Phase

0.69 miles

Learn More »

Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery

Chronic stroke participants will be recruited from the Chang Gung Memorial Hospital and then were randomly assigned to 1 of the 4 groups: MT+tDCS, MT+sham tDCS, MT, and CI groups. The participants in each group receive equivalent amounts of treatment. Analysis of covariance (ANCOVA), controlling for the pretest differences, will ...

Phase N/A

0.69 miles

Learn More »

A Study of ABBV-181 in Participants With Advanced Solid Tumors

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine. The study will consist ...

Phase

0.84 miles

Learn More »

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Patients will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The primary objective of this study is to assess the efficacy of durvalumab compared to SoC in terms of OS (Overall Survival) in patients with NSCLC

Phase

0.84 miles

Learn More »

Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)

Osteoarthritis (OA) is a common and incurable disease for the elderly in Taiwan, so it is an important mission to develop a new treatment for OA. Recently, cellular therapy is a new and popular medical treatment around the world, one of them is "Mesenchymal Stromal Cells (MSCs)". MSCs are found ...

Phase

0.84 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Pharmacokinetics of UB-921 in Healthy Volunteers

This is an open-label, two-part, dose-escalation and comparative pharmacokinetics study of UB-921 in healthy male volunteers. There will be two parts: dose escalation study (Main Study) and comparative pharmacokinetics study (Sub-study).

Phase

0.84 miles

Learn More »

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of Ineligibility For or Refusal of a Taxane Regimen

This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide alone in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone) and failure of, ineligibility for, or refusal of a ...

Phase

0.84 miles

Learn More »